12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ublituximab: Phase Ib final data

Final data from 11 evaluable patients with relapsed CLL who received >=1 prior therapy with fludarabine in an open-label, French Phase Ib trial showed that ublituximab led to 5 partial responses at 6 months, all of which were maintained at 12 months of follow-up. Median PFS was not reached at 12 months. The most common treatment-related adverse event reported...

Read the full 271 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >